120 related articles for article (PubMed ID: 34029540)
1. Design, synthesis, and antitumor activity of PLGA nanoparticles incorporating a discovered benzimidazole derivative as EZH2 inhibitor.
Elkot HA; Ragab I; Saleh NM; Amin MN; Al-Rashood ST; El-Messery SM; Hassan GS
Chem Biol Interact; 2021 Aug; 344():109530. PubMed ID: 34029540
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas.
Wu D; Zeng X; Zhao Y; Qin M; Gong P
Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588
[TBL] [Abstract][Full Text] [Related]
3. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and activity evaluation of quinolinone derivatives as EZH2 inhibitors.
Cai J; You H; Qin X; Wang Y; Li W
Bioorg Med Chem Lett; 2024 Jun; 105():129726. PubMed ID: 38580135
[TBL] [Abstract][Full Text] [Related]
5. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
Zhou B; Liang X; Mei H; Qi S; Jiang Z; Wang A; Zou F; Liu Q; Liu J; Wang W; Hu C; Chen Y; Wang Z; Wang B; Wang L; Liu J; Liu Q
J Med Chem; 2021 Oct; 64(20):15170-15188. PubMed ID: 34664960
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of benzimidazole derivatives as novel human Pin1 inhibitors.
Ma T; Huang M; Li A; Zhao F; Li D; Liu D; Zhao L
Bioorg Med Chem Lett; 2019 Jul; 29(14):1859-1863. PubMed ID: 31103446
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays.
Wu Y; Hu J; Ding H; Chen L; Zhang Y; Liu R; Xu P; Du D; Lu W; Liu J; Liu Y; Liu YC; Lu J; Zhang J; Yao Z; Luo C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3813-7. PubMed ID: 27289323
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: In vitro and in vivo evaluation.
Vakilinezhad MA; Amini A; Dara T; Alipour S
Colloids Surf B Biointerfaces; 2019 Dec; 184():110515. PubMed ID: 31585308
[TBL] [Abstract][Full Text] [Related]
9. Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction.
Du D; Xu D; Zhu L; Stazi G; Zwergel C; Liu Y; Luo Z; Li Y; Zhang Y; Zhu K; Ding Y; Liu J; Fan S; Zhao K; Zhang N; Kong X; Jiang H; Chen K; Zhao K; Valente S; Min J; Duan W; Luo C
J Med Chem; 2021 Jun; 64(12):8194-8207. PubMed ID: 34077206
[TBL] [Abstract][Full Text] [Related]
10. Discovery, design, and synthesis of indole-based EZH2 inhibitors.
Gehling VS; Vaswani RG; Nasveschuk CG; Duplessis M; Iyer P; Balasubramanian S; Zhao F; Good AC; Campbell R; Lee C; Dakin LA; Cook AS; Gagnon A; Harmange JC; Audia JE; Cummings RT; Normant E; Trojer P; Albrecht BK
Bioorg Med Chem Lett; 2015 Sep; 25(17):3644-9. PubMed ID: 26189078
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method.
Misawa K; Yamaotsu N; Hirono S
J Comput Aided Mol Des; 2021 May; 35(5):601-611. PubMed ID: 33635506
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer.
Li X; Gera L; Zhang S; Chen Y; Lou L; Wilson LM; Xie ZR; Sautto G; Liu D; Danaher A; Mamouni K; Yang Y; Du Y; Fu H; Kucuk O; Osunkoya AO; Zhou J; Wu D
Theranostics; 2021; 11(14):6873-6890. PubMed ID: 34093859
[No Abstract] [Full Text] [Related]
13. Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors.
He H; Hu X; Teng F; Liu Z; Zhang Q; Feng Z; Feng Q; Yu L
Bioorg Med Chem Lett; 2020 Mar; 30(5):126957. PubMed ID: 31959420
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon.
Wu P; Zhou Q; Zhu H; Zhuang Y; Bao J
BMC Cancer; 2020 Apr; 20(1):354. PubMed ID: 32345258
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma.
Tu Y; Sun Y; Qiao S; Luo Y; Liu P; Jiang ZX; Hu Y; Wang Z; Huang P; Wen S
J Med Chem; 2021 Jul; 64(14):10167-10184. PubMed ID: 34196564
[TBL] [Abstract][Full Text] [Related]
16. Covalent inhibitors of EZH2: Design, synthesis and evaluation.
Zhang Q; Chen X; Hu X; Duan X; Wan G; Li L; Feng Q; Zhang Y; Wang N; Yu L
Biomed Pharmacother; 2022 Mar; 147():112617. PubMed ID: 34998031
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of benzomorpholine derivatives as novel EZH2 inhibitors for anti-non-small cell lung cancer activity.
Feng Q; He H; Gao T; Zhang Q; Liu Z; Tao X; Zhu Y; Zhang L; Yu L
Mol Divers; 2019 Aug; 23(3):681-696. PubMed ID: 30612258
[TBL] [Abstract][Full Text] [Related]
18. Poly-(Lactic-co-Glycolic) Acid Nanoparticles for Synergistic Delivery of Epirubicin and Paclitaxel to Human Lung Cancer Cells.
Sharma N; Kumari RM; Gupta N; Syed A; Bahkali AH; Nimesh S
Molecules; 2020 Sep; 25(18):. PubMed ID: 32947799
[TBL] [Abstract][Full Text] [Related]
19. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Antitumor Efficacy of Curcumin-Loaded PLGA Nanoparticles Coated with Unique Fungal Hydrophobin.
Sun L; Xu H; Xu JH; Wang SN; Wang JW; Zhang HF; Jia WR; Li LS
AAPS PharmSciTech; 2020 Jun; 21(5):171. PubMed ID: 32529560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
